First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

(MedPage Today) — Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).
Approval was supported by findings from the TRANSCEND FL trial and stipulates…